HIV/AIDS

Key considerations for differentiated antiretroviral therapy delivery for specific populations: children, adolescents, pregnant and breastfeeding women and key populations

Authors:
WHO, CDC, PEPFAR, USAID, IAS

Key considerations for differentiated antiretroviral therapy delivery for specific populations: children, adolescents, pregnant and breastfeeding women and key populations

Publication details

Number of pages: 66
Publication date: July 2017
Languages: English, French
WHO reference number: WHO/HIV/2017.23

Downloads

Overview

In 2016, WHO published consolidated guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection. As part of this revision, WHO recognized that, as ART is scaled up and countries adopt the “treat all” policy, ART services will need to be differentiated to provide adapted packages of care to people living with HIV with varied clinical needs.

At the time the 2016 WHO consolidated ARV guidelines were developed, there was limited evidence and experience around how these criteria should be applied to pregnant and breastfeeding women, children and adolescents and members of key populations. Since then, appreciation has been growing that these types of clients may also benefit from models of care specifically for clinically stable clients.

This document outlines the rationale for and features of differentiated ART delivery for clinically stable clients in these populations.

Related topics

Related publications